DK0521842T3 - Tumorantigenspecifikt antistof - Google Patents

Tumorantigenspecifikt antistof

Info

Publication number
DK0521842T3
DK0521842T3 DK92850166T DK92850166T DK0521842T3 DK 0521842 T3 DK0521842 T3 DK 0521842T3 DK 92850166 T DK92850166 T DK 92850166T DK 92850166 T DK92850166 T DK 92850166T DK 0521842 T3 DK0521842 T3 DK 0521842T3
Authority
DK
Denmark
Prior art keywords
antibody
specific antibody
tumor antigen
antigen
culturing
Prior art date
Application number
DK92850166T
Other languages
English (en)
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of DK0521842T3 publication Critical patent/DK0521842T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92850166T 1991-07-03 1992-07-03 Tumorantigenspecifikt antistof DK0521842T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
DK0521842T3 true DK0521842T3 (da) 1999-06-14

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92850166T DK0521842T3 (da) 1991-07-03 1992-07-03 Tumorantigenspecifikt antistof

Country Status (19)

Country Link
US (1) US5552293A (da)
EP (1) EP0521842B1 (da)
JP (1) JP3194020B2 (da)
KR (1) KR100246681B1 (da)
AT (1) ATE171193T1 (da)
AU (2) AU658198B2 (da)
CA (1) CA2073124C (da)
DE (1) DE69226990T2 (da)
DK (1) DK0521842T3 (da)
EE (1) EE03031B1 (da)
ES (1) ES2124250T3 (da)
FI (1) FI109207B (da)
HU (2) HU218084B (da)
IE (1) IE80841B1 (da)
IL (1) IL102390A (da)
NO (1) NO315472B1 (da)
NZ (1) NZ243435A (da)
SE (1) SE9102074D0 (da)
WO (2) WO1993001302A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3851126A1 (en) 2003-05-20 2021-07-21 ImmunoGen, Inc. Maytansinoid-cell-binding agent conjugates
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
NZ566245A (en) * 2005-08-11 2012-04-27 Matossian Rogers Arpi Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
ES2533992T3 (es) 2005-08-24 2015-04-16 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpo maitansinoide
RU2519089C2 (ru) 2008-08-05 2014-06-10 Торэй Индастриз, Инк. Способ обнаружения злокачественных опухолей
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
UA116524C2 (uk) 2011-03-29 2018-04-10 Іммуноджен, Інк. Спосіб одержання кон'югата антитіло-майтансиноїд
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
JP7161938B2 (ja) 2016-01-10 2022-10-27 ネオティーエックス セラピューティクス リミテッド スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
MX2021013908A (es) 2019-05-15 2022-03-11 Neotx Therapeutics Ltd Tratamiento para el cáncer.
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
DK0610179T3 (da) * 1990-07-20 1997-03-24 Pharmacia & Upjohn Ab Målspecifikke antistof-superantigenkonjugater og fremstilling deraf
EP0540612A1 (en) * 1990-07-20 1993-05-12 Pharmacia AB Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Also Published As

Publication number Publication date
HU211512A9 (en) 1995-11-28
KR100246681B1 (ko) 2000-04-01
ATE171193T1 (de) 1998-10-15
NZ243435A (en) 1994-10-26
AU1942592A (en) 1993-01-07
EP0521842A3 (da) 1994-01-26
WO1993001303A1 (en) 1993-01-21
HUT71193A (en) 1995-11-28
IL102390A (en) 1996-01-19
NO315472B1 (no) 2003-09-08
EP0521842A2 (en) 1993-01-07
DE69226990T2 (de) 1999-03-25
IE922188A1 (en) 1993-01-13
AU658198B2 (en) 1995-04-06
IE80841B1 (en) 1999-03-24
IL102390A0 (en) 1993-01-14
SE9102074D0 (sv) 1991-07-03
FI935970A0 (fi) 1993-12-31
NO934777L (no) 1994-02-11
HU9400011D0 (en) 1994-05-30
ES2124250T3 (es) 1999-02-01
DE69226990D1 (de) 1998-10-22
CA2073124A1 (en) 1993-01-04
CA2073124C (en) 2007-06-19
EP0521842B1 (en) 1998-09-16
FI935970A (fi) 1993-12-31
HU218084B (hu) 2000-05-28
WO1993001302A1 (en) 1993-01-21
US5552293A (en) 1996-09-03
JP3194020B2 (ja) 2001-07-30
FI109207B (fi) 2002-06-14
JPH05276987A (ja) 1993-10-26
AU2292092A (en) 1993-02-11
NO934777D0 (no) 1993-12-22
EE03031B1 (et) 1997-08-15

Similar Documents

Publication Publication Date Title
DK0521842T3 (da) Tumorantigenspecifikt antistof
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
EP0822830A4 (en) HUMAN ANTIBODIES FROM IMMUNIZED XENOMAS
EP0584715A3 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper.
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
DE3684211D1 (da)
FI853389A0 (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
EP0218158A3 (en) Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
ATE243742T1 (de) Hybridzelle und deren verwendung zur herstellung eines arzneimittels zur induktion einer tumorimmunität
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
ITRM920100A0 (it) Sequenze genetiche per l'antigene 90k associato a tumori.
DK182188A (da) Humant tumorassocieret antigen
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.